VeriSperse® is a cold water dispersible (CWD) resveratrol powder, specifically designed to increase its bioavailability. 

Utilizing exclusive, patented LipiSperse® technology means that resveratrol’s normally limited ability to dissolve in aqueous environments (such as the stomach), is enhanced and can disperse freely, increasing VeriSperse®’s bioavailability and therefore efficacy as it becomes more readily available.

VeriSperse® LipiSperse® advantage

VeriSperse® has an equilibrium established between the LipiSperse® on the powder surface and the solution. Repulsive forces between the particles prevent agglomeration or aggregation: allowing VeriSperse® to have proper particle dispersion. Proper dispersion offers advantages in absorption, dosage requirements, efficacy and final product quality.

VeriSperse Advantage over standard resveratrol:

  • high active loads
  • improved functionality
  • enhanced bioavailability

VeriSperse’s enhanced bioavailability is scientifically validated through:

  • a human pilot
  • pharmacokinetic study

LipiSperse can be customized for:

  • customer requirements
  • regulatory frameworks
  • dosage format(s)

Veri-Sperse® can be used in multiple product sectors and applications:

  • nutraceutical
  • cosmetic
  • pharmaceutical
  • veterinary
  • antibacterial
  • dietary supplements
  • food and beverage

Clinical research

Resveratrol versus VeriSperse® under the microscope

When under the microscope, VeriSperse®’s superior absorption can be easily seen. Picture A1 shows standard resveratrol behaving as a single agglomerated large particle, whereas A2 shows the primary VeriSperse® particle is well dispersed in water.

Increased bioavailability of resveratrol using the Novel Dispersion Technology System (LipiSperse®)

Seven healthy male (n=3) and female (n=4) subjects were recruited to take part in this pilot study of resveratrol (100 mg) with and without LipiSperse®. Resveratrol pharmacokinetics were determined from venous blood samples taken prior to dosing (t = 0), followed by intervals of 0.5, 1, 2, 3, 4, 5, 6, 7, and 8 hours post supplementation.

Participants consumed the capsules on a fasted stomach followed by the consumption of a low-fat breakfast and lunch containing no resveratrol. This method was incorporated to minimize any external substance (e.g. dietary fat) influencing the absorption of the supplement via increased intestinal absorption.

The aim of the present study was to demonstrate that absorption of trans-resveratrol is increased when combined with LipiSperse®. This study showed no trans-resveratrol enters circulation. This is due to the conversion of the transresveratrol in the gastrointestinal tract via the microbiome to resveratrol conjugates. This study therefore showed that a single dose of trans-resveratrol with LipiSperse® resulted in a 1.6-fold increase in the resulting resveratrol-sulfate conjugate (Table 1 and Figure 1) and a 2-fold increase in glucuronide conjugate (Table 1 and Figure 2).